Squarepoint’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $124M | Buy |
198,567
+35,753
| +22% | +$24.3M | 0.14% | 128 |
|
|
2026
Q1 | $126M | Buy |
162,814
+160,128
| +5,962% | +$123M | 0.15% | 118 |
|
|
2025
Q4 | $2.07M | Sell |
2,686
-63,585
| -96% | -$43.2M | ﹤0.01% | 2036 |
|
|
2025
Q3 | $37.3M | Sell |
66,271
-231,420
| -78% | -$131M | 0.04% | 505 |
|
|
2025
Q2 | $156M | Buy |
297,691
+13,688
| +5% | +$7.64M | 0.16% | 117 |
|
|
2025
Q1 | $180M | Buy |
284,003
+29,424
| +12% | +$20.2M | 0.22% | 71 |
|
|
2024
Q4 | $181M | Buy |
254,579
+213,479
| +519% | +$179M | 0.18% | 84 |
|
|
2024
Q3 | $43.2M | Buy |
41,100
+38,226
| +1,330% | +$42.5M | 0.07% | 277 |
|
|
2024
Q2 | $3.02M | Sell |
2,874
-2,397
| -45% | -$2.32M | 0.01% | 1744 |
|
|
2024
Q1 | $5.07M | Sell |
5,271
-37,892
| -88% | -$36M | 0.01% | 1430 |
|
|
2023
Q4 | $37.9M | Buy |
43,163
+27,596
| +177% | +$22.7M | 0.07% | 306 |
|
|
2023
Q3 | $12.8M | Buy |
15,567
+11,432
| +276% | +$8.98M | 0.03% | 676 |
|
|
2023
Q2 | $2.97M | Sell |
4,135
-13,402
| -76% | -$10.3M | 0.01% | 1407 |
|
|
2023
Q1 | $14.4M | Buy |
17,537
+16,737
| +2,092% | +$12.6M | 0.06% | 400 |
|
|
2022
Q4 | $577K | Buy |
+800
| New | +$590K | ﹤0.01% | 2183 |
|
|
2022
Q1 | – | Sell |
-25,927
| Closed | -$16.4M | – | 3395 |
|
|
2021
Q4 | $16.4M | Sell |
25,927
-15,060
| -37% | -$9.26M | 0.04% | 364 |
|
|
2021
Q3 | $24.8M | Buy |
40,987
+35,504
| +648% | +$22M | 0.07% | 252 |
|
|
2021
Q2 | $3.06M | Sell |
5,483
-37,009
| -87% | -$18.7M | 0.01% | 960 |
|
|
2021
Q1 | $20.1M | Buy |
42,492
+11,451
| +37% | +$5.58M | 0.12% | 180 |
|
|
2020
Q4 | $15M | Buy |
31,041
+21,587
| +228% | +$11.7M | 0.11% | 171 |
|
|
2020
Q3 | $5.29M | Buy |
+9,454
| New | +$5.73M | 0.07% | 330 |
|
|
2020
Q2 | – | Sell |
-9,185
| Closed | -$4.49M | – | 2480 |
|
|
2020
Q1 | $4.49M | Buy |
+9,185
| New | +$3.79M | 0.11% | 227 |
|
|
2019
Q4 | – | Sell |
-52,787
| Closed | -$14.6M | – | 2744 |
|
|
2019
Q3 | $14.6M | Sell |
52,787
-4,799
| -8% | -$1.42M | 0.13% | 193 |
|
|
2019
Q2 | $18M | Buy |
57,586
+9,171
| +19% | +$3.05M | 0.18% | 134 |
|
|
2019
Q1 | $19.9M | Buy |
+48,415
| New | +$19.9M | 0.21% | 101 |
|
|
2018
Q2 | – | Sell |
-11,000
| Closed | -$3.79M | – | 1995 |
|
|
2018
Q1 | $3.79M | Buy |
11,000
+5,377
| +96% | +$1.87M | 0.06% | 375 |
|
|
2017
Q4 | $2.11M | Sell |
5,623
-35,422
| -86% | -$14.3M | 0.04% | 545 |
|
|
2017
Q3 | $18.4M | Buy |
41,045
+32,791
| +397% | +$15.6M | 0.35% | 62 |
|
|
2017
Q2 | $4.05M | Buy |
8,254
+6,355
| +335% | +$2.78M | 0.08% | 307 |
|
|
2017
Q1 | $736K | Buy |
1,899
+597
| +46% | +$221K | 0.02% | 718 |
|
|
2016
Q4 | $478K | Sell |
1,302
-3,379
| -72% | -$1.28M | 0.02% | 857 |
|
|
2016
Q3 | $1.88M | Buy |
+4,681
| New | +$1.88M | 0.12% | 195 |
|
|
2016
Q2 | – | Sell |
-4,726
| Closed | -$1.7M | – | 1306 |
|
|
2016
Q1 | $1.7M | Buy |
+4,726
| New | +$1.95M | 0.13% | 213 |
|
Other funds holding REGN
Squarepoint's REGN Position: Q2 2026 in Review
Squarepoint increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q2 2026, buying an estimated $24.3M and bringing the position to 198,567 shares worth $124M. The position accounts for 0.14% of the portfolio, ranked #128.
Squarepoint first reported a position in REGN in Q1 2016 and has held it in 33 quarters since. The position peaked at $181M in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Squarepoint held 198,567 shares of Regeneron Pharmaceuticals worth $124M as of Q2 2026.
- Squarepoint bought 35,753 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $24.3M.
- Regeneron Pharmaceuticals made up 0.14% of Squarepoint's portfolio in Q2 2026, its #128 holding.
- Squarepoint first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 33 quarters since.
- Squarepoint's Regeneron Pharmaceuticals position peaked at $181M in Q4 2024.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.